TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate.

Kabagambe, Edmond K.
Glasser, Stephen P.
Ordovas, Jose M.
Warodomwichit, Daruneewan.
Tsai, Michael Y.
Hopkins, Paul N.
Borecki, Ingrid B.
Wojczynski, Mary.
Arnett, Donna K.
2009

Background: Inflammation is implicated in causing diabetes. We tested whether transcription factor 7 like-2 (TCF7L2) gene polymorphisms (rs12255372 and rs7903146), consistently associated with type 2 diabetes, are associated with plasma concentrations of inflammatory markers before and after three weeks of daily treatment with fenofibrate... read more

Permanent URL
http://hdl.handle.net/10427/010201
Original publication
Kabagambe, Edmond, Stephen P. Glasser, Jose M. Ordovas, Daruneewan Warodomwichit, Michael Y. Tsai, Paul N. Hopkins, Ingrid B. Borecki, Mary Wojczynski, and Donna K. Arnett. "TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate." Diabetology & Metabolic Syndrome 1, no. 1 (12, 2009): 1-4.
ID: tufts:17569
To Cite: DCA Citation Guide
Usage: Detailed Rights